Novel MRI assessment of treatment response in HIV-associated NAFLD: a randomized trial of an SCD1 inhibitor (ARRIVE Trial)

Aramchol, an oral stearoyl-coenzyme-A-desaturase-1 (SCD1) inhibitor, has been shown to reduce hepatic-fat content in patients with primary nonalcoholic-fatty-liver-disease (NAFLD), however, its effect in patients with HIV-associated NAFLD is unknown. The ARRIVE trial was a double-blind, randomized,...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Hepatology
Hoofdauteurs: Ajmera, Veeral H., Cachay, Edward, Ramers, Christian, Vodkin, Irine, Bassirian, Shirin, Singh, Seema, Mangla, Neeraj, Bettencourt, Richele, Aldous, Jeannette L, Park, Daniel, Lee, Daniel, Blanchard, Jennifer, Mamidipalli, Adrija, Boehringer, Andrew, Aslam, Saima, Leinhard, Olof Dahlqvist, Richards, Lisa, Sirlin, Claude, Loomba, Rohit
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2019
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7164416/
https://ncbi.nlm.nih.gov/pubmed/31013363
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.30674
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items